Partner John Zabriskie was quoted in a CPJ Blog post, “Supreme Court could limit FOIA, curtail investigative reporting,” about a pending Supreme Court case that could limit the amount of information that is subject to disclosure under a Freedom of Information Act (FOIA) request.
Zabriskie said FMI, an industry group representing over 40,000 retail food stores that is seeking to broaden the definition of what is considered “confidential” under the act, has a strong case. Although the case appears to “pit journalistic interests against a company’s commercial proprietary interests,” he said, “businesses are genuinely motivated by not having their competitively valued information disclosed.”
Zabriskie said FMI, an industry group representing over 40,000 retail food stores that is seeking to broaden the definition of what is considered “confidential” under the act, has a strong case. Although the case appears to “pit journalistic interests against a company’s commercial proprietary interests,” he said, “businesses are genuinely motivated by not having their competitively valued information disclosed.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”